Tags : Coronavirus

GSK Signs an Agreement with Vir Biotechnology to Develop Solutions

Shots: GSK will make equity investment to gain access to Vir’s technology of $250M, priced at $37.73 (a 10% premium to closing share price on March 27, 2020). The equity investment and collaboration will complete at the same time & are conditional upon customary conditions including regulatory review by appropriate regulatory agencies under Hart-Scott-Rodino Act […]Read More

Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses

Shots: Moleculin will provide its lead candidate, WP1122, and related inhibitors along with technical support while UTMB will investigate candidates against multiple viruses including COVID-19, in connection with UTMB’s CBEID UTMB’s CBEID collaborates with the Galveston National Laboratory, which is funded by NIAID the US Department of Defense, the US Centers for Disease Control & […]Read More

Vir Biotechnology Collaborates with NIH Vaccine Research Center to Advance

Shots: Vir and NIAID will jointly identify and optimize combinations of Ab against coronaviruses, including SARS-CoV-2, SARS, and MERS along with Ab that may show effectiveness across additional types of coronaviruses The collaboration allows Vir to access VRC’s research experience with coronaviruses to accelerate the development of Ab targeting the unmet medical needs of patients […]Read More

GSK Signs a Research Collaboration with Clover for the Evaluation

Shots: GSK to provide pandemic adjuvant system to Clover to evaluate S-Trimer in preclinical studies while Clover has largest commercial-scale cGMP biomanufacturing capabilities in China involved in rapid scale-up and produce new coronavirus vaccine The focus of the collaboration is to evaluate the combination of GSK’s pandemic adjuvant system with Clover’s S-Trimer as a vaccine […]Read More

Zydus Cadila Launches a Research Program to Develop Vaccine Against

Shots: Zydus has initiated an accelerated research program with multiple teams in India and the EU to develop a vaccine against coronavirus, 2019-nCoV (COVID-19) based on two approaches The two approaches include the development of DNA vaccine by Zydus’ VTC and a live attenuated recombinant measles virus vectored vaccine by Zydus’ Etna Biotech to combat […]Read More

Regeneron Expands its Existing Collaboration with HHS’BARDA to Develop Antibody

Shots: The collaboration leverages Regeneron’s VelociSuite technologies including the VelocImmune platform to develop mAb as monothx. or in combination to treat coronavirus (2019-nCoV) In 2017, HHS and Regeneron collaborated for discovery, research, development and manufacturing of an Abs targeting up to 10 pathogens including influenza virus and 2019-nCoV Regeneron’s VelociSuite technologies including the VelocImmune platform […]Read More

Johnson & Johnson Initiates the Development of Vaccines Against Coronavirus

Shots: J&J launches a multi-pronged response to the Coronavirus (2019-nCoV or Wuhan coronavirus) outbreak and collaborating with others to screen a library of antiviral therapies The vaccine program leverages Janssen’s AdVac and PER.C6 technologies, providing the ability to rapidly upscale production of the optimal vaccine therapy. The company utilize its same technology in its Ebola […]Read More